Pricing
Compounded Tirzepatide Cost: A 2026 Buyer's Guide
Tirzepatide floors run above semaglutide at the same providers. Here's the current picture.
What does compounded tirzepatide actually cost across the captured market, why does it run higher than semaglutide, and how do you compare programs fairly? This 2026 buyer's guide answers all three with current captured figures.
The current captured picture
Across the tracked compounded tirzepatide standard-dose injection programs, the lowest rankable effective monthly cost captured is Trimi's $125 (annual plan, $1,500 for the year; read first-party 2026-09-04), with NexLife at $139 on a 12-month plan and the lowest month-to-month figure at $169, flat at every dose; month-to-month and shorter-term rates run higher everywhere. Other providers advertise lower headlines but are excluded from the ranking for approximate, dose-dependent, or conflicting pricing — shown with their reasons on the tirzepatide pricing page. All figures are provider-reported, not checkout-verified.
Lowest captured: Trimi at $125.00; highest: Ready Med at $449.00. Bar colour reflects evidence status. All figures provider-reported or calculated, not checkout-verified.
View chart data as a table
| Provider | $ effective monthly | Evidence status |
|---|---|---|
| Trimi | $125.00 | PROVIDER REPORTED |
| NexLife | $139.00 | PROVIDER REPORTED |
| Yucca Health | $225.00 | PROVIDER REPORTED |
| Join Josie | $233.00 | PROVIDER REPORTED |
| Mochi Health | $278.00 | PROVIDER REPORTED |
| Eden | $298.00 | CALCULATED |
| Ready Med | $449.00 | PROVIDER REPORTED |
Why tirzepatide runs higher than semaglutide
At the same providers, compounded tirzepatide typically costs $30–$100/month more than semaglutide at the maintenance dose. The gap reflects the more expensive active ingredient and tirzepatide's premium positioning as the dual-receptor (GLP-1 and GIP) medication associated with greater average weight loss in trials. Importantly, the higher price doesn't guarantee the trial outcomes in a compounded form — it reflects ingredient cost and positioning, not compounded-specific evidence.
How to compare tirzepatide programs fairly
Same discipline as any GLP-1: compute effective monthly cost at your maintenance dose (medication plus membership plus fees plus shipping, over months supplied), get the renewal rate not the intro, and note the amount due today on prepaid plans. Watch for dose surcharges specifically — tirzepatide's higher doses are where tiered pricing bites hardest. And compare tirzepatide against tirzepatide only; its price floor is structurally above semaglutide's, so cross-medication comparison is meaningless.
Where compounded tirzepatide sits against alternatives
Compare compounded tirzepatide cash pricing against manufacturer cash-pay for the approved product (Zepbound/Mounjaro), which has come down, and against an insured copay if you have coverage — an insured approved-product copay can beat any cash compounded price. These are different product classes; we never rank compounded against approved in one ordering, but the cost comparison across classes is worth doing before you commit.
Frequently asked questions
How much does compounded tirzepatide cost in 2026?
The lowest rankable captured effective monthly cost is $125 (Trimi's annual plan) and $139 (NexLife's 12-month plan), with the lowest month-to-month figure at $169 (NexLife); some providers advertise lower headlines but are excluded for approximate or dose-dependent pricing. All figures are provider-reported, not checkout-verified — confirm current pricing and dose coverage directly.
Why is compounded tirzepatide more expensive than semaglutide?
Its more expensive active ingredient and premium dual-receptor positioning push its floor $30–$100/month above semaglutide at maintenance dose. The higher price reflects ingredient cost and positioning, not a guarantee of trial outcomes in compounded form.
Is compounded tirzepatide worth it over semaglutide?
That's a clinical question, not a price one — the two have different mechanisms, side-effect profiles, and individual responses. Trials suggest greater average weight loss with tirzepatide, but "on average" isn't "for everyone." Decide with a prescriber, then let price inform logistics.
Evidence status. Pricing figures are provider-reported or independently calculated as of 2026-07-20, not checkout-verified. Compounded medications are not FDA approved. This article is consumer education, not medical advice. See the methodology for how figures are gated and the public evidence ledger for per-figure sources. Found an error? Use the corrections route.
Update (2026-08-09): figures re-read in the August 2026 price check — floors unchanged, brand context moved.
Full decision table (2026-08-09): the cost-ranked hub — all-in vs month-to-month, dose behavior, fees, shipping, pharmacy disclosure per program.